Combining Fluoxetine 20 mg with Aripiprazole 5 mg for Depression
Yes, combining fluoxetine (Prozac) 20 mg daily with aripiprazole (Abilify) 5 mg daily is an appropriate and evidence-based augmentation strategy for treatment-resistant depression, with aripiprazole demonstrating superior remission rates compared to other augmentation options.
Evidence for Aripiprazole Augmentation
The combination of an SSRI (like fluoxetine) with low-dose aripiprazole is well-supported for patients who have inadequate response to antidepressant monotherapy. Aripiprazole augmentation at doses of 2-5 mg has been shown to achieve optimal efficacy with better tolerability than higher doses 1. In a large randomized controlled trial of 1,147 patients with treatment-resistant depression, adjunctive aripiprazole produced significantly greater improvements in depressive symptoms (MADRS score reduction of -10.1 vs -6.4 for placebo, p<0.001) and achieved remission rates of 36.8% versus 18.9% for placebo at 6 weeks 2.
Most importantly, a direct comparison study found that aripiprazole augmentation achieved significantly higher remission rates (55.4%) compared to bupropion augmentation (34.0%, p=0.031) at 6 weeks 3. This makes aripiprazole one of the most effective augmentation strategies available.
Optimal Dosing Strategy
The 5 mg daily dose you're considering is within the optimal range. Meta-analysis data shows that the dose-efficacy curve for aripiprazole peaks between 2-5 mg daily, with no additional benefit from higher doses up to 20 mg 1. This is critical because:
- Starting at 2.5 mg and titrating to 5 mg reduces akathisia risk by 50% compared to starting at 10 mg 4
- Lower doses (2-5 mg) maintain efficacy while minimizing metabolic side effects and extrapyramidal symptoms
- The FDA-approved dose range is 2-20 mg daily, but lower doses are preferred for tolerability 5
Important Drug Interaction Consideration
Fluoxetine significantly inhibits CYP2D6, which metabolizes aripiprazole 6, 7. This interaction means:
- Fluoxetine will increase aripiprazole plasma concentrations
- The combination may effectively create higher aripiprazole exposure than the nominal 5 mg dose suggests
- This interaction actually supports using the lower 5 mg dose rather than higher doses
- Monitor for side effects more carefully, particularly akathisia, sedation, and metabolic effects
Fluoxetine at 20 mg daily converts approximately 43% of normal metabolizers to poor metabolizers through CYP2D6 inhibition 7. While this interaction exists, it doesn't contraindicate the combination—it simply reinforces the wisdom of using lower aripiprazole doses.
Monitoring and Safety
Key adverse effects to monitor:
- Akathisia (most common, occurs in ~10-15% of patients): Start at 2.5 mg if concerned, titrate slowly
- Weight gain and metabolic effects: More problematic at higher doses and in patients already overweight 8
- Extrapyramidal symptoms: Less likely at 5 mg than higher doses 9
- Sedation: May occur but often improves with time
The combination has high completion rates (83%) and low discontinuation rates due to adverse events (6.2%) 2, indicating good overall tolerability.
Clinical Algorithm
- Confirm inadequate response to fluoxetine 20 mg after at least 4-8 weeks at therapeutic dose 10
- Start aripiprazole at 2.5 mg daily for 3-7 days to assess tolerability
- Increase to 5 mg daily if tolerated
- Assess response at 1-2 weeks: Many patients show rapid improvement within 1-2 weeks 4
- Continue for 6 weeks to assess full response
- Consider increasing to 10 mg only if inadequate response at 5 mg and no tolerability issues
- Do not exceed 10 mg given the fluoxetine interaction and lack of additional benefit at higher doses
Comparison to Alternatives
This combination is superior to:
- Switching to another antidepressant (similar efficacy but delays treatment) 11
- Bupropion augmentation (lower remission rates) 3, 8
- Higher-dose aripiprazole (no additional benefit, more side effects) 1
The fluoxetine 20 mg + aripiprazole 5 mg combination represents an evidence-based, well-tolerated augmentation strategy that should be considered a first-line option for treatment-resistant depression.